Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and/or Angiotensin II Receptor Blocker (ARB) Drugs, With or Without Spironolactone

Next Previous
Trial Profile

A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and/or Angiotensin II Receptor Blocker (ARB) Drugs, With or Without Spironolactone

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Patiromer (Primary) ; Losartan; Spironolactone
  • Indications Hyperkalaemia
  • Focus Therapeutic Use
  • Acronyms AMETHYST-DN
  • Sponsors Relypsa

Most Recent Events

  • 01 Jul 2023 Results of post hoc pooled analysis (n=578) assessing the effect of patiromer on sP in patients with CKD, hyperkalemia, and hyperphosphatemia published in the American Journal of Kidney Diseases
  • 11 Jun 2019 Results assessing the effect of Patiromer in in a subgroup of patients 75 Years or Older with Diabetic Kidney Disease and Hyperkalemia Receiving a RAAS Inhibitor, presented at the 79th Annual Scientific Sessions of the American Diabetes Association
  • 11 Apr 2018 According to the Relypsa media release, findings from pooled analysis from this and other two trials (OPAL-HK and TOURMALINE) will be presented in a poster session at the National Kidney Foundation's (NKF) 2018 Spring Clinical Meetings (SCM18).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top